98%
921
2 minutes
20
Background: To analyze the effect of type 2 diabetes (T2D) on cardiorespiratory fitness.
Methods: A multilevel model using restricted maximum likelihood method was used to analyze pooled data. Inclusion criteria included adults aged >18 years, one group of individuals needed to have been diagnosed with T2D, the control group must not have had insulin resistance, the study must report peak oxygen uptake, there was no exercise training before tests of functional capacity, and subjects may not have had overt cardiovascular disease, cancer, transplant surgery, or bariatric surgery. Moderators assessed were sample demographics (age, body mass index, sex, and time since T2D diagnosis) and cardiovascular outcomes (eg, echocardiographic variables, blood pressure).
Results: Absolute (cohorts n=30; subjects n=1152; mean difference, -0.29 L/min [95% CI, -0.37 to -0.22 L/min]; <0.0001) and relative peak oxygen uptake (cohorts n=11; subjects n=1191; mean difference, -4.68 mL/kg per min; 95% CI, -6.94 to -2.42 mL/kg per min; =0.001) were significantly reduced in the T2D group compared with control. Time since T2D diagnosis (β coefficient=-0.04, =0.05) was a significant moderator of the absolute peak oxygen uptake pooled outcome. Early mitral inflow velocity/early mitral annulus velocity (β coefficient=-1.72, =0.004) and left atrial volume index (β coefficient=-1.41, =0.02) were significant moderators of the relative peak oxygen uptake model.
Conclusions: Markers of cardiac diastolic function (early mitral inflow velocity/early mitral annulus velocity and left atrial volume index) and time since diabetes diagnosis may contribute to exercise intolerance in T2D, although there is a lack of data in young/older adults and newly diagnosed individuals. As cardiorespiratory fitness predicts both all-cause mortality and cardiovascular morbidity and mortality, these data have important implications for risk reduction in individuals with T2D.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12132642 | PMC |
http://dx.doi.org/10.1161/JAHA.124.035721 | DOI Listing |
Obesity (Silver Spring)
September 2025
Eli Lilly and Company, Indianapolis, Indiana, USA.
Objective: SURMOUNT-MAINTAIN aims to evaluate the efficacy and safety of reducing the tirzepatide dose and/or continuing the maximum tolerated dose (MTD) versus placebo in maintaining body weight (BW) reduction achieved with tirzepatide MTD.
Methods: This Phase 3b, multicenter, randomized, parallel-arm, double-blinded, placebo-controlled, 52-week clinical trial is in progress comparing treatment with once weekly tirzepatide (5 mg and/or MTD of 15 mg or 10 mg) versus placebo in achieving BW reduction maintenance from the initial 60-week open-label weight-loss period on tirzepatide MTD, in adults with obesity (BMI ≥ 30 kg/m or ≥ 27 kg/m with ≥ 1 obesity-related comorbidity, excluding type 2 diabetes). The primary endpoint is percent maintenance of BW reduction achieved during the weight-loss period at Week 112 among those who reached a BW plateau (i.
Alzheimers Dement
September 2025
Department of Public Health, California State University, Fullerton, California, USA.
Introduction: We investigated the associations between diabetes (type 2), hypertension and hypercholesterolemia with mild cognitive impairment (MCI) and Alzheimer's disease (AD) diagnoses by race-ethnicity and sex.
Methods: Data (n = 22,950) were derived via the National Alzheimer's Coordinating Center. Logistic regression was used to assess the relationship between each comorbid condition and MCI and AD.
Trends Pharmacol Sci
September 2025
Department of Biosciences and Bioinformatics & Suzhou Municipal Key Lab of Biomedical Sciences and Translational Immunology, School of Science, Xi'an Jiaotong-Liverpool University, Suzhou, China; Biomedical Research Center, School of Science, Engineering and Environment, University of Salford, Manch
Regulatory T cells (Tregs) play a pivotal role in maintaining immune tolerance and sustaining immunological homeostasis. Emerging evidence indicates that Treg characteristics and functional alterations can significantly contribute to the pathogenesis of autoimmune diseases including type 1 diabetes mellitus (T1DM). Notably, recent studies have established a positive correlation between diminished numbers of Tregs and the onset of T1DM.
View Article and Find Full Text PDFEur J Intern Med
September 2025
Department of Haematology, Beaumont Hospital, Dublin 9, Ireland. Electronic address:
Diabetes Res Clin Pract
September 2025
Health Education Department, and Department of Endocrinology and Diabetes, Diabetes Treatment Center, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
Background: Despite advances, glycemic control in people with type 2 diabetes (PwT2D) treated with oral antidiabetic medications (ADMs) often remains suboptimal. Continuous glucose monitoring (CGM) has shown promise in diabetes management, offering real-time insights into glucose trends. This study evaluates the impact of transitioning from conventional self-monitoring of blood glucose (SMBG) to CGM on glycemic outcomes and self-management in PwT2D receiving oral ADMs.
View Article and Find Full Text PDF